Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The New England Journal of Medicine Notable Articles of 2018 recognizes the significance of the TAYLORx | CCTG MAC12 study, in addition, the Journal of Clinical Oncology has also named TAILORx as one of the most important clinical research advances of 2018.
CCTG is pleased to announce that the CRC7 has met its accrual goal of 1180 patients and has been closed to accrual. CCTG CRC.7 (N1048) trial: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)
Effective April 15, 2019, participants at our member sites will be required to attest to completion of this one-time training requirement prior to becoming active on a trial Participants List.
Ibrutinib, the first in class Bruton’s tyrosine kinase inhibitor is the first targeted therapy approved in chronic lymphocytic leukemia (CLL) and quickly became the standard of care treatment for relapsed and refractory CLL based on its demonstrated efficacy and safety. Prior to this trial Ibrutinib had not been compared against a standard of care chemo-immunotherapy.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
These CCTG trials have been formally permanently closed/terminated. No further ethics approvals or folow up data are required, more information can be found on the CCTG website under the "Toolbox".
CCTG trials BL13 and IND237 have been centrally activated with further information please visit the trial pages.
This is a reminder to obscure all personal identifiers of participants from reports and correspondence sent to CCTG and to provide an update on our privacy breach process. The Canadian Cancer Trials Group has recently sent an email to Centre Representatives and Contact Clinical Research Associates on December 21, 2018 outlining how to prevent a privacy breach and what to expect if one occurs.
